Background: Fibrinogen is mainly responsible for determining the viscosity of whole blood. In peripheral arterial disease (PAD) the fibrinogen concentration seems to affect the microcirculation flow.
Aim: To study the effects of an abrupt reduction of fibrinogen on the hemodynamics of the lower extremities and the clinical picture of patients with PAD.
Methods: Ten patients affected by various stages of PAD underwent 1 session of fibrinogen apheresis (TheraSorb, Miltenyi Biotec, Germany). Laboratory parameters of endothelial activation were assessed before and after the session, as well as walking distance (WD), the ankle-brachial index and laser Doppler flowmetry.
Results: A significant reduction in the laboratory parameters was observed: fibrinogen (50%), total cholesterol (18%), LDL cholesterol (24%), sE-selectin (23%), sICAM-1 (19%) and sVCAM-1 (10%). The procoagulant factors, factor VIII and von Willebrand factor, did not vary significantly. Both pain-free and total WD were significantly improved (p < 0.003 and p <0.006, respectively), the ankle-brachial index remained unchanged, and laser Doppler flowmetry showed a modest but not significant increase.
Conclusions: Fibrinogen apheresis allowed us to study the effects of an acute modification of fibrinogen in PAD, on both some aspects of the endothelial function and on the hemodynamics, demonstrating an improvement of WD and a minimal increase in the skin microcirculation.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1159/000109101 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Background: Although revascularization is first-line therapy for chronic limb-threatening ischemia (CLTI), there are no established treatments for patients in whom revascularization is not (or is a poor) option, including CLTI that has responded poorly to revascularization. This study verified the efficacy of the Rheocarna, a novel apheresis device, for no-option CLTI or poor-response CLTI after revascularization.
Methods And Results: This multicenter retrospective observational study analyzed 221 patients (221 limbs) with no- or poor-option CLTI (mean [±SD] age 71±10 years; males, 70.
The effects of plerixafor on the hemostatic system in patients undergoing stem cell mobilization.
Hematol Oncol Stem Cell Ther
January 2025
Department of Hematology, Ankara University School of Medicine, Ankara, Turkey.
Despite numerous reports on the procoagulant activities of G-CSF, the effect of plerixafor on the hemostatic system is not clearly understood. This study aims to evaluate the effects of plerixafor on the hemostatic system when used for autologous stem cell mobilization (ASCM) for poor mobilizers (PM) with lymphoma and multiple myeloma. Patients who were performed ASCM with plerixafor in combination with GCSF were prospectively enrolled.
View Article and Find Full Text PDFSuccessful treatment for a patient with antiphospholipid syndrome and decreased protein S activity exacerbated by heparin-induced thrombocytopenia: A case report.
Medicine (Baltimore)
November 2024
Division of Hematology and Rheumatology, Department of Medicine, Nihon University School of Medicine, Tokyo, Japan.
Rationale: Antiphospholipid antibody syndrome and protein S/C deficiency are diseases that are sometimes complicated by thrombus, and heparin-induced thrombosis (HIT) has also been reported.
Patient Concerns: A male patient in his 60s with elevated D-dimer and superior mesenteric thrombus and portal vein thrombus underwent partial small intestine resection and thrombectomy. After administration of heparin, aortic thrombosis and pulmonary embolism occurred along with rapid thrombocytopenia.
Cross-Sectional Survey to Assess Hospital System Readiness for Hemorrhage During and After Cesarean Delivery in Africa.
Anesth Analg
November 2024
From the Department of Anaesthesia and Perioperative Medicine, Groote Schuur Hospital and University of Cape Town, Cape Town, South Africa.
Article Synopsis
- Mothers in Africa face a significantly higher risk of dying from complications after cesarean deliveries compared to high-income countries, primarily due to postpartum hemorrhage (PPH).
- A survey conducted among anesthesiologists and obstetricians in 140 hospitals across Africa aimed to assess the readiness of these facilities to implement World Health Organization (WHO) guidelines for preventing and treating PPH.
- The survey found that while many hospitals had access to key medications like oxytocin and crystalloids, there were gaps in the availability of some critical treatments, such as heat-stable carbetocin and intrauterine balloon tamponades, highlighting the need for improved resources and training in PPH management.
Extending the post-thaw shelf-life of cryoprecipitate when stored at refrigerated temperatures.
Vox Sang
December 2024
Research and Development, Australian Red Cross Lifeblood, Alexandria, New South Wales, Australia.
Article Synopsis
- The study investigates the storage of thawed cryoprecipitate at 1-6°C to potentially extend its shelf-life beyond the current 6-hour limit, which leads to high wastage.
- Over a 14-day period, various coagulation factors were monitored in mini- and full-size cryoprecipitate packs from apheresis and whole blood collections.
- Results showed that while Factor VIII levels decreased significantly after 24 hours, most samples still met quality specifications up to 14 days post-thaw, indicating that refrigerated storage could be a viable solution.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!